Zhang Ya-Ni, Chen Yu-Pei, OuYang Pu-Yun, Lu Tai-Xiang, Xie Fang-Yun, Han Fei, Chen Chun-Yan
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, Guangdong 510060, China.
Ther Adv Med Oncol. 2025 Jan 31;17:17588359251316094. doi: 10.1177/17588359251316094. eCollection 2025.
The poor prognosis of locoregionally advanced nasopharyngeal carcinoma (LANPC) due to the high incidence of metastasis necessitates effective treatment strategies. Synergistic effects have been observed when anti-programmed death-1 (PD-1) inhibitors are combined with chemotherapy or targeted therapy.
To compare the efficacy and safety of induction chemotherapy in combination with nimotuzumab with or without anti-PD-1 inhibitors for LANPC.
Retrospective study.
In total, 319 patients with LANPC were retrospectively enrolled between December 2017 and November 2022. The primary endpoint was progression-free survival (PFS). Propensity score matching was performed to adjust for potential confounders.
Overall, 150 patients were included after propensity score matching. The immunotherapy + nimotuzumab + chemotherapy (INC) group ( = 50) had a higher 3-year PFS rate (96.6% (95% confidence interval (CI): 93.2-100.0)) than the nimotuzumab + chemotherapy (NC) group ( = 100) (79.8% (95% CI: 75.6-84.0)). The INC group had a hazard ratio of 0.16 (95% CI: 0.02-1.22; = 0.04). The objective response rates were 100% and 99% for the INC and NC groups, respectively. Grade ⩾3 treatment-related adverse events were reported in eight (5.3%) patients, and hyponatremia (2.0%) was the most common. Grade ⩾3 immune-related adverse events (rash and reactive capillary proliferation) were reported in two (4.0%) patients.
INC demonstrated remarkable anti-tumor activity with acceptable safety for LANPC.
由于转移发生率高，局部区域晚期鼻咽癌（LANPC）预后较差，因此需要有效的治疗策略。抗程序性死亡-1（PD-1）抑制剂与化疗或靶向治疗联合使用时已观察到协同效应。
比较诱导化疗联合尼妥珠单抗加或不加抗PD-1抑制剂治疗LANPC的疗效和安全性。
回顾性研究。
2017年12月至2022年11月间，共回顾性纳入319例LANPC患者。主要终点是无进展生存期（PFS）。进行倾向评分匹配以调整潜在混杂因素。
总体而言，倾向评分匹配后纳入150例患者。免疫治疗+尼妥珠单抗+化疗（INC）组（n = 50）的3年PFS率（96.6%（95%置信区间（CI）：93.2 - 100.0））高于尼妥珠单抗+化疗（NC）组（n = 100）（79.8%（95% CI：75.6 - 84.0））。INC组的风险比为0.16（95% CI：0.02 - 1.22；P = 0.04）。INC组和NC组的客观缓解率分别为100%和99%。8例（5.3%）患者报告了≥3级治疗相关不良事件，低钠血症（2.0%）最为常见。2例（4.0%）患者报告了≥3级免疫相关不良事件（皮疹和反应性毛细血管增生）。
INC对LANPC显示出显著的抗肿瘤活性，安全性可接受。
